2013
DOI: 10.1002/jms.3264
|View full text |Cite
|
Sign up to set email alerts
|

Shotgun‐proteomics‐based clinical testing for diagnosis and classification of amyloidosis

Abstract: Shotgun proteomics technology has matured in the research laboratories and is poised to enter clinical laboratories. However, the road to this transition is sprinkled with major technical unknowns such as long-term stability of the platform, reproducibility of the technology and clinical utility over traditional antibody-based platforms. Further, regulatory bodies that oversee the clinical laboratory operations are unfamiliar with this new technology. As a result, diagnostic laboratories have avoided using sho… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
56
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 69 publications
(58 citation statements)
references
References 59 publications
1
56
0
Order By: Relevance
“…In particular, proteomic amyloid typing has already moved into clinical practice and has been implemented as a clinical test [75].…”
Section: Amyloidosis Typingmentioning
confidence: 99%
See 2 more Smart Citations
“…In particular, proteomic amyloid typing has already moved into clinical practice and has been implemented as a clinical test [75].…”
Section: Amyloidosis Typingmentioning
confidence: 99%
“…However, major differences among the methods exist, principally involving the strategies used to fractionate the tissue proteins prior to MS, and the data analysis criteria that allow classifying one of the identified proteins as the amyloid constituent. A widely employed approach is based on selection of amyloid-positive areas by laser capture dissection/microdissection (LCD/LCM), retrieval/extraction of proteins, and shotgun liquid chromatography-tandem mass spectrometry (LC-MS/MS analysis) [50,67,68,[75][76][77]. In the final step of the process, a pathologist calls the amyloid subtype from the list of identified proteins (which include both fibrillar and fibril-associated proteins), by considering the most abundant amyloidogenic species detected across all microdissections.…”
Section: Amyloidosis Typingmentioning
confidence: 99%
See 1 more Smart Citation
“…Furthermore, unlike immunohistochemistry, MS/MS identification is independent of protein conformation. With significant technical advantages over immunohistochemistry, MS has been proposed as the new gold standard for amyloid typing based on promising reports of diagnostic accuracy [6,7].…”
Section: Amyloid Typing Methodsmentioning
confidence: 99%
“…Thus the stakes are high and accurate typing of amyloid deposits is critical for major management decisions. To address this important clinical problem, the author's group utilized a semi-quantitative bottom-up shotgun MS-based proteomics approach to develop clinical tests to diagnose and classify systemic and localized amyloidosis [10]. The first test was developed to address the cases where a diagnosis of amyloidosis was established on FFPE biopsy material but the etiology was unclear.…”
mentioning
confidence: 99%